# NGM Biopharmaceuticals

> NGM Biopharmaceuticals is a private South San Francisco biotech translating biology into first-in-class medicines, anchored by its GDF15/GFRAL antagonist NGM120 in Phase 2 trials for cancer cachexia and hyperemesis gravidarum.

- **Founded:** 2007
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Jin-Long Chen (Co-founder, former Chief Scientific Officer), David Goeddel (Co-founder), Alex DePaoli (Co-founder)
- **Team size:** ~82
- **Products:** NGM120, In-house discovery engine
- **Notable:** IPO on Nasdaq in 2019, Advanced NGM120 into Phase 2 for two distinct indications, Acquired and taken private by The Column Group in April 2024

## Products & services

- **NGM120** — GDF15/GFRAL antagonist antibody in Phase 2 trials for cancer cachexia and hyperemesis gravidarum.
- **In-house discovery engine** — Biology-driven platform identifying novel targets across oncology, ophthalmology, liver and cardio-metabolic disease.

## Achievements

- IPO on Nasdaq in 2019
- Advanced NGM120 into Phase 2 for two distinct indications
- Acquired and taken private by The Column Group in April 2024
- Appointed Wendy Yeh, M.D. as Chief Medical Officer in February 2025

## Latest updates

- **2025-02** — Named Wendy Yeh, M.D. Chief Medical Officer.
- **2024-07** — Closed additional financing tied to private operations.
- **2024-04** — Completed take-private transaction with The Column Group.

## Links

- Website: https://ngmbio.com
- LinkedIn: https://www.linkedin.com/company/ngm-biopharmaceuticals
- Twitter/X: https://twitter.com/ngmbio

---

Profile page: https://yespress.io/ngm-biopharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-05-19